Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: A report by the Nagasaki CML Study Group

International Journal of Hematology

Volumn 89, Issue 3, 2009, Pages 319-325

  Sakai, Mari ^a   Miyazaki, Yasushi ^a   Matsuo, Emi ^a   Moriuchi, Yukiyoshi ^b   Hata, Tomoko ^a   Fukushima, Takuya ^a   Imaizumi, Yoshitaka ^a   Imanishi, Daisuke ^a   Taguchi, Jun ^a   Iwanaga, Masako ^a   Tsushima, Hideki ^b   Inoue, Yoriko ^b   Takasaki, Yumi ^b   Tsuchiya, Takeshi ^a   Komoda, Minori ^a   Ando, Koji ^a   Horio, Kensuke ^a   Moriwaki, Yuji ^b   Tominaga, Shinya ^a   Itonaga, Hidehiro ^a   Nagai, Kazuhiro ^a   Tsukasaki, Kunihiro ^a   Tsutsumi, Chizuko ^b   Sawayama, Yasushi ^b   Yamasaki, Reishi ^b   Ogawa, Daisuke ^b   Kawaguchi, Yasuhisa ^b   Ikeda, Shuichi ^b   Yoshida, Shinichiro ^b   Onimaru, Yasuyuki ^b   Tawara, Masayuki ^b   Atogami, Sunao ^b   Koida, Satoshi ^b   Joh, Tatsuro ^b   Yamamura, Masaomi ^b   Matsuo, Yuji ^b   Soda, Hisashi ^b   Nonaka, Hiroaki ^b   Jinnai, Itsuro ^b   Kuriyama, Kazutaka ^b   Tomonaga, Masao ^a   more..

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Nagasaki CML Study Group   (Japan)

Author keywords

CML; Imatinib; Trough concentration

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY SIZE; BODY SURFACE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT RESPONSE; DRUG EFFECT; JAPAN; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY SIZE; FEMALE; HUMANS; JAPAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL RATE; TIME FACTORS;

EID: 67649218742     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0263-z     Document Type: Article

References (17)

1. R Hehlmann A Hochhaus M Baccarani European LeukemiaNet 2007 Chronic myeloid leukaemia Lancet 370 342 50 10.1016/S0140-6736(07)61165-9 (Pubitemid 47094995)
2. G Borthakur JE Cortes 2004 Imatinib mesylate treat chronic myelogenous leukemia Int J Hematol 79 411 9
3. M Deininger E Buchdunger BJ Druker 2005 The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2640 53 10.1182/blood-2004-08-3097 (Pubitemid 40446252)
4. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004 10.1056/NEJMoa022457 (Pubitemid 36302244)
5. TM Hughes J Kaeda S Branford Z Rudzki A Hochhaus ML Hensley 2003 Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423 32 10.1056/NEJMoa030513 (Pubitemid 37211057)
6. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 17 10.1056/NEJMoa062867 (Pubitemid 44903745)
7. E Matsuo Y Miyazaki C Tsutsumi Y Inoue R Yamasaki T Hata 2007 Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in Nagasaki Prefecture, Japan Int J Hematol 85 132 9 10.1532/IJH97.06157 (Pubitemid 46365550)
8. S Picard K Titier G Etienne E Teilhet D Ducint MA Bernard 2007 Tough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 3496 9 10.1182/blood-2006-07-036012 (Pubitemid 46572540)
9. RA Larson BJ Drucker F Guiihot SG O'Brien GJ Riviere T Krahnke 2008 Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 4022 8 10.1182/blood-2007-10-116475
10. R Bakhtiar J Lohne L Ramos L Khemani M Hayes M Tse 2002 High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (GCP 74588) in human plasma using liquid chromatography-tandem mass spectrometry J Chromatogr A 768 325 40
11. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 20 10.1182/blood-2006-02-005686 (Pubitemid 44394987)
12. B Peng P Lloyd H Schran 2005 Clinical pharmacokinetics of imatinib Clin Pharmacokinet 44 879 94 10.2165/00003088-200544090-00001 (Pubitemid 41252840)
13. B Peng M Hayes D Resta ARP Brian BJ Druker M Talpaz 2004 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 935 42 10.1200/JCO.2004.03.050 (Pubitemid 41103606)
14. M Talpaz NP Shah H Kantarjian N Donato J Nicoll R Paquette 2006 Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2531 41 10.1056/NEJMoa055229 (Pubitemid 43882349)
15. H Kantarjian F Giles L Wunderle K Bhalla S O'Brien B Wassmann 2006 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2542 51 10.1056/NEJMoa055104 (Pubitemid 43882350)
16. E Jabbour J Cortes HM Kantarjian S Giralt D Jones F Giles 2006 Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure Blood 108 1421 3 10.1182/blood-2006-02-001933 (Pubitemid 44232047)
17. H Kantarjian M Talpaz S O'Brien G Garcia-Manero S Verstovsed F Giles 2004 High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2873 8